Crinetics Pharmaceuticals (CRNX) Current Assets (2017 - 2026)

Crinetics Pharmaceuticals' Current Assets history runs 10 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Current Assets rose 2.43% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 2.43% YoY), while the FY2025 annual figure was $1.0 billion, down 23.78% from the prior year.
• Current Assets was $1.3 billion for Q1 2026 at Crinetics Pharmaceuticals, up from $1.0 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.4 billion in Q4 2024 to a low of $284.8 million in Q2 2023.
• Historically, Current Assets has averaged $779.6 million across 5 years, with a median of $874.8 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Current Assets slumped 31.58% in 2023, then jumped 207.14% in 2024.
• A 5-year view of Current Assets shows it stood at $345.2 million in 2022, then soared by 66.33% to $574.2 million in 2023, then soared by 139.55% to $1.4 billion in 2024, then declined by 23.78% to $1.0 billion in 2025, then increased by 26.14% to $1.3 billion in 2026.
• The last three Current Assets figures came in at $1.3 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.